The roses funding opportunity goals are: execute a balanced science program based on discipline-specific guidance from the national academies of sciences, engineering, and medicine, administration…

Eureka Scientific, Inc., a small disadvantaged business specializing in advanced research and consulting services in astrophysics, planetary science, and space science, has been awarded a $38.5K research grant by NASA's Shared Services Center under the Research Opportunities in Space and Earth Sciences (ROSES) funding program. The award, issued on September 10, 2025, with a completion date of September 9, 2026, supports the company's ongoing contributions to federal scientific research initiatives. No set-aside designation was applied to this award. ROSES represents NASA's primary mechanism for soliciting and funding basic and applied research proposals across multiple scientific disciplines, guided by recommendations from the National Academies of Sciences, Engineering, and Medicine, and aligned with administration priorities and congressional direction.

Eureka Scientific will perform research activities at its facility in Piedmont, California, continuing its established track record of delivering sophisticated scientific research, data analysis, and technical consulting to federal agencies. The company's prior work has included archival investigations of astronomical phenomena, data reduction and analysis from space observatories, and collaborative research with institutions such as NASA Goddard Space Flight Center and the University of Maryland. This award reflects Eureka Scientific's demonstrated expertise in areas including X-ray spectroscopy, ultraviolet photometry, machine learning, and advanced observational research, positioning the firm as a consistent contributor to NASA's scientific objectives and the broader federal research enterprise.

The roses funding opportunity goals are: execute a balanced science program based on discipline-specific guidance from the national academies of sciences, engineering, and medicine, administration priorities, and direction from congress. Participat